Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGMT | P16455 | 9/20 | 0.68 |
| ▸ | CDK1 | P06493 | 2/20 | 0.68 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.68 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.68 |
| ▸ | CDK2 | P24941 | 2/20 | 0.68 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | MPO | P05164 | 1/20 | 0.56 |
| ▸ | TPO | P07202 | 1/20 | 0.56 |
| ▸ | EPX | P11678 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16852229 | 0.91 | MGMT (0.64) | MGMTCDK1CCNB1CCNA2CDK2 | |
| SCHEMBL6358672 | 0.85 | MGMT (0.66) | MGMTCDK1CCNB1CCNA2CDK2 | |
| SCHEMBL16828164 | 0.83 | MGMT (0.56) | MGMTCDK1CCNB1CCNA2CDK2 | |
| SCHEMBL16828160 | 0.83 | MGMT (0.56) | MGMTCDK1CCNB1CCNA2CDK2 | |
| SCHEMBL7983396 | 0.83 | CDK1 (0.58) | MGMTCDK1CCNB1CCNA2CDK2 | |
| SCHEMBL2054835 | 0.81 | MGMT (1.00) | MGMTCDK1CCNB1CCNA2CDK2 | |
| SCHEMBL16828192 | 0.81 | MGMT (0.54) | MGMTCDK1CCNB1CCNA2CDK2 | |
| SCHEMBL6362726 | 0.80 | MGMT (0.63) | MGMTCDK1CCNB1CCNA2CDK2 | |
| SCHEMBL6362719 | 0.80 | MGMT (0.63) | MGMTCDK1CCNB1CCNA2CDK2 | |
| SCHEMBL16828180 | 0.80 | MGMT (0.52) | MGMTCDK1CCNB1CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9364408-B2 | Hair dye agent comprising aminopyrimidine derivatives | HENKEL AG & CO. KGAA (DE) | 2016-06-14 | — | — | US | claimed |
| EP-2906191-A1 | HAIR DYE AGENT COMPRISING AMINOPYRIMIDINE DERIVATIVES | Henkel AG&Co. KGAA (DE) | 2015-08-19 | — | — | EP | claimed |
| US-20150209258-A1 | HAIR DYE AGENT COMPRISING AMINOPYRIMIDINE DERIVATIVES | HENKEL AG & CO. KGAA (DE) | 2015-07-30 | — | — | US | claimed |
| US-20140296264-A1 | MGMT INHIBITOR COMBINATIONS FOR THE TREATMENT OF NEOPLASTIC DISORDERS | CASE WESTERN RESERVE UNIVERSITY | 2014-10-02 | — | — | US | claimed |
| US-8791081-B2 | MGMT inhibitor combination for the treatment of neoplastic disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-07-29 | — | — | US | claimed |
| WO-2014056760-A1 | HAIR DYE AGENT COMPRISING AMINOPYRIMIDINE DERIVATIVES | HENKEL AG & CO. KGAA (DE) | 2014-04-17 | — | — | WO | claimed |
| US-20100093647-A1 | MGMT INHIBITOR COMBINATION FOR THE TREATMENT OF NEOPLASTIC DISORDERS | LIU LILI | 2010-04-15 | — | — | US | claimed |
| CN-101380297-A | Compound platinum medicine sustained-release agent | JINAN SHUAIHUA PHARMACEUTICAL (CN) | 2009-03-11 | — | — | CN | claimed |
| WO-2008109417-A1 | MGMT INHIBITOR COMBINATIONS FOR THE TREATMENT OF NEOPLASTIC DISORDERS | CASE WESTERN RESERVE UNIVERSITY (US) | 2008-09-12 | — | — | WO | claimed |
| CN-101254170-A | An anticancer sustained release injection carrying clorfarabine and its synergist | JINAN KANGQUAN PHARMACEUTICAL (CN) | 2008-09-03 | — | — | CN | claimed |
| CN-1861047-A | Slow-releasing injection contg. vasoinhibitor and potentiator type anticarcinogen | SHUAIHUA MEDICINE SCIENCE AND (CN) | 2006-11-15 | — | — | CN | claimed |
| CN-1861049-A | Anticancer drug sustained-release injection containing gemcitabine | LANJIN BIOENGINEERING CO LTD S (CN) | 2006-11-15 | — | — | CN | claimed |
| CN-1861050-A | Anticancer drug sustained-release injection loaded with platinum compound and synergist thereof | LANJIN BIOENGINEERING CO LTD S (CN) | 2006-11-15 | — | — | CN | claimed |
| CN-1850039-A | Compound platinum medicine slow-release agent | SHUAIHUA MEDICINE SCIENCE TECH (CN) | 2006-10-25 | — | — | CN | claimed |
| CN-1846679-A | Sustained-release injection containing methotrexate and synergist thereof | JINAN SHUAIHUA MEDICINE SCI TE (CN) | 2006-10-18 | — | — | CN | claimed |
| CN-1846673-A | Slow-released anticancer medicine prepn containing pyrimidine medicine | JINAN SHUAIHUA MEDICINE SCI TE (CN) | 2006-10-18 | — | — | CN | claimed |
| CN-1846676-A | Sustained-release injection containing fluorouracil synergist and preparation method thereof | JINAN SHUAIHUA MEDICINE SCI TE (CN) | 2006-10-18 | — | — | CN | claimed |
| CN-1846687-A | Slow-release agent containing taxane and synergist thereof | JINAN KANGQUAN MEDICINE SCI TE (CN) | 2006-10-18 | — | — | CN | claimed |
| CN-1733300-A | Anticancer implantation agent | KONG QINGZHONG (CN) | 2006-02-15 | — | — | CN | claimed |
| CN-1628853-A | Anti-cancer medicine composition | KONG QINGZHONG (CN) | 2005-06-22 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093647-A1 | MGMT INHIBITOR COMBINATION FOR THE TREATMENT OF NEOPLASTIC DISORDERS | MGMT, MSH2, UNG | MGMT 1/4885CDK1 566/4885CCNB1 569/4885 |
| US-20140296264-A1 | MGMT INHIBITOR COMBINATIONS FOR THE TREATMENT OF NEOPLASTIC DISORDERS | MGMT, MSH2, UNG | MGMT 1/4885CDK1 566/4885CCNB1 531/4885 |
| US-20150209258-A1 | HAIR DYE AGENT COMPRISING AMINOPYRIMIDINE DERIVATIVES | KRT18, DPYD, DHFR | MGMT 77/4885CDK1 507/4885CCNB1 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.